BOSTON, Feb 8 (Reuters) - U.S. regulators warned Biogen Idec Inc. (BIIB.O: Quote, Profile, Research) last December to stop disseminating misleading promotional material about its cancer drug Zevalin, according to a document released on Wednesday by the U.S. Food and Drug Administration.
